



Proton Therapy for CNS Tumors

Guest Editors:

Prof. Dr. Beate Timmermann

Department of Particle Therapy,
West German Proton Therapy
Centre Essen (WPE), University
Hospital Essen, German Cancer
Consortium (DKTK), 45122 Essen,
Germany

Dr. Julie A. Bradley

Department of Radiation
Oncology, University of Florida
College of Medicine, Jacksonville,
FL, USA

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Radiotherapy is an important and highly effective part of modern multimodality management of CNS tumors. However, radiotherapy is known to cause a broad range of adverse effects, potentially having a significant negative impact on quality of life. Thus, strategies that mitigate late effects are needed. With regard to radiotherapy, techniques are attractive when able to better protect normal tissue and critical organs at risk. Due to its particular physical characteristics, Proton therapy (PT) can achieve high dose conformality to the target volume while sparing normal tissue. Important technological advances have managed to make PT more robust and deliverable to a huge variety of tumor entities. PT is often preferred in tumor sites in the vicinity of particularly vulnerable tissue and in tumors requiring high radiation doses. Therefore, CNS and base of skull tumors of the CNS are the predominant diagnoses in the majority of proton facilities and clinical evidence is increasing. This Special Issue on proton therapy for CNS tumors will highlight the role of PT in CNS tumors, covering various clinical, physical, and biological aspects.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)